Systems biology of primary CNS lymphoma: From genetic aberrations to modeling in mice

Acta Neuropathologica

Volumn 127, Issue 2, 2014, Pages 175-188

  Deckert, Martina ^a   Montesinos Rongen, Manuel ^a   Brunn, Anna ^a   Siebert, Reiner ^b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

Astrocyte; Genetics; Microglia; PCNSL; T cells

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; B LYMPHOCYTE RECEPTOR; CBL PROTEIN; CD79B ANTIGEN; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN D; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN M; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; METHOTREXATE; MYC PROTEIN; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN BCL 2; PROTEIN KINASE PIM 1; RITUXIMAB; THYROID TRANSCRIPTION FACTOR 1; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR PAX5;

B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL DIFFERENTIATION; CELL HOMING; CELL PROLIFERATION; CELL SURVIVAL; GENOTYPE; GERMINAL CENTER; HUMAN; IMMUNITY; IMMUNOPHENOTYPING; INFLAMMATORY INFILTRATE; NONHUMAN; PHENOTYPE; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; REVIEW; SOMATIC HYPERMUTATION; SYSTEMS BIOLOGY; TUMOR MICROENVIRONMENT;

ANIMALS; B-LYMPHOCYTES; CELL DIFFERENTIATION; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM NEOPLASMS; DISEASE MODELS, ANIMAL; EPIGENOMICS; GENOTYPE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MICE; MUTATION; SYSTEMS BIOLOGY;

EID: 84896708044     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-013-1202-x     Document Type: Review

References (104)

1. Alldinger S, Fonfara S, Kremmer E, Baumgärtner W (2000) Up-regulation of the hyaluronate receptor CD44 in canine distemper demyelinated plaques. Acta Neuropathol 99:138-146
2. Baraniskin A, Kuhnhenn J, Schlegel U et al (2011) Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood 117:3140-3146
3. Barrans SL, Fenton JA, Banham A, Owen RG, Jack AS (2004) Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood 104:2933-2935
4. Bartholomäus I, Kawakami N, Odoardi F et al (2009) Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions. Nature 462:94-98
5. Bashir R, Coakham H, Hochberg F (1992) Expression of LFA-1/ICAM-1 in CNS lymphomas: possible mechanism for lymphoma homing into the brain. J Neurooncol 12:103-110
6. Basso K, Dalla-Favera R (2010) BCL6: master regulator of the germinal center reaction and key oncogene in B cell lymphomagenesis. Adv Immunol 105:193-210
7. Basso K, Dalla-Favera R (2012) Roles of BCL6 in normal and transformed germinal center B cells. Immunol Rev 247:172-183
8. Bechmann I, Priller J, Kovac A et al (2001) Immune surveillance of mouse brain perivascular spaces by blood-borne macrophages. Eur J Neurosci 14:1651-1658
9. Ben Abdelwahed R, Cosette J, Donnou S et al (2013) Lymphoma B-cell responsiveness to CpG-DNA depends on the tumor microenvironment. J Exp Clin Cancer Res 32:18
10. Ben Abdelwahed R, Donnou S, Ouakrim H et al (2013) Preclinical study of ublituximab, a glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas. Invest Ophthalmol Vis Sci 54:3657-3665
11. Booman M, Douwes J, Glas AM et al (2006) Mechanisms and effects of loss of human leukocyte antigen class II expression in immune-privileged site-associated B-cell lymphoma. Clin Cancer Res 12:2698-2705
12. Brunn A, Montesinos-Rongen M, Strack A et al (2007) Expression pattern and cellular sources of chemokines in primary central nervous system lymphoma. Acta Neuropathol 114:271-276
13. Brunn A, Nagel I, Montesinos-Rongen M et al (2013) Frequent triple-hit expression of MYC, BCL2, and BCL6 in primary lymphoma of the central nervous system and absence of a favorable MYClowBCL2low subgroup may underlie the inferior prognosis as compared to systemic diffuse large B cell lymphomas. Acta Neuropathol doi. doi: 10.1007/s00401-00013-01169-00407
14. Butler MP, Iida S, Capello D et al (2002) Alternative translocation breakpoint cluster region 5′ to BCL-6 in B-cell non-Hodgkin's lymphoma. Cancer Res 62:4089-4094
15. Cady FM, O'Neill BP, Law ME et al (2008) Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course. J Clin Oncol 26:4814-4819
16. Chu LC, Eberhart CG, Grossman SA, Herman JG (2006) Epigenetic silencing of multiple genes in primary CNS lymphoma. Int J Cancer 119:2487-2491
17. Cobbers JM, Wolter M, Reifenberger J et al (1998) Frequent inactivation of CDKN2A and rare mutation of TP53 in PCNSL. Brain Pathol 8:263-276
18. Courts C, Brunn A, Montesinos-Rongen M et al (2009) Preferential expression of truncated isoforms of FOXP1 in primary central nervous system lymphoma. J Neuropathol Exp Neurol 68:972-976
19. Courts C, Montesinos-Rongen M, Brunn A et al (2008) Recurrent inactivation of the PRDM1 gene in primary central nervous system lymphoma. J Neuropathol Exp Neurol 67:720-727
20. Courts C, Montesinos-Rongen M, Martin-Subero JI et al (2007) Transcriptional profiling of the nuclear factor-kappaB pathway identifies a subgroup of primary lymphoma of the central nervous system with low BCL10 expression. J Neuropathol Exp Neurol 66:230-237
21. Deckert M, Brunn A, Montesinos-Rongen M, Terreni MR, Ponzoni M (2013) Primary lymphomas of the central nervous system - a diagnostic challenge. Hematol Oncol. doi: 10.1002/jon.2087
22. Deckert M, Paulus W (2007) Malignant lymphomas. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumors pathology ans genetics of tumours of the nervous System, 4th edn. IRAC, Lyon, pp 188-192
23. Deckert M, Soltek S, Geginat G et al (2001) Endogenous interleukin-10 is required for prevention of a hyperinflammatory intracerebral immune response in Listeria monocytogenes meningoencephalitis. Infect Immun 69:4561-4571
24. Deckert-Schlüter M, Buck C, Weiner D et al (1997) Interleukin-10 downregulates the intracerebral immune response in chronic toxoplasma encephalitis. J Neuroimmunol 76:167-176
25. Dominguez-Sola D, Victora GD, Ying CY et al (2012) The proto-oncogene MYC is required for selection in the germinal center and cyclic reentry. Nat Immunol 13:1083-1091
26. Donnou S, Galand C, Daussy C et al (2011) Immune adaptive microenvironment profiles in intracerebral and intrasplenic lymphomas share common characteristics. Clin Exp Immunol 165:329-337
27. Ferreri AJ, Dell'Oro S, Capello D et al (2004) Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas. Br J Haematol 126:657-664
28. Fischer L, Hummel M, Korfel A, Lenze D, Joehrens K, Thiel E (2011) Differential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomas. Neuro Oncol 13:1090-1098
29. Frei K, Lins H, Fontana A (1994) Production and function of IL-10 in the central nervous system. Schweiz Arch Neurol Psychiatr 145:30-31
30. Frei K, Lins H, Schwerdel C, Fontana A (1994) Antigen presentation in the central nervous system. The inhibitory effect of IL-10 on MHC class II expression and production of cytokines depends on the inducing signals and the type of cell analyzed. J Immunol 152:2720-2728
31. Frei K, Nadal D, Pfister HW, Fontana A (1993) Listeria meningitis: identification of a cerebrospinal fluid inhibitor of macrophage listericidal function as interleukin 10. J Exp Med 178:1255-1261
32. Gallo P, Sivieri S, Rinaldi L et al (1994) Intrathecal synthesis of interleukin-10 (IL-10) in viral and inflammatory diseases of the central nervous system. J Neurol Sci 126:49-53
33. Gonzalez-Aguilar A, Idbaih A, Boisselier B et al (2012) Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res 18:5203-5211
34. Gonzalez-Gomez P, Bello MJ, Arjona D et al (2003) CpG island methylation of tumor-related genes in three primary central nervous system lymphomas in immunocompetent patients. Cancer Genet Cytogenet 142:21-24
35. Green TM, Young KH, Visco C et al (2012) Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30:3460-3467
36. Haegel H, Tölg C, Hofmann M, Ceredig R (1993) Activated mouse astrocytes and T cells express similar CD44 variants. Role of CD44 in astrocyte/T cell binding. J Cell Biol 122:1067-1077
37. Horn H, Ziepert M, Becher C et al (2013) MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 121:2253-2263
38. Ishiguro A, Suzuki Y, Inaba Y, Komiyama A, Koeffler HP, Shimbo T (1996) Production of interleukin-10 in the cerebrospinal fluid in aseptic meningitis of children. Pediatr Res 40:610-614
39. Jahnke K, Muldoon LL, Varallyay CG et al (2009) Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma. Neuro Oncol 11:503-513
40. Jin Kim K, Kanellopoulos-Langevin C, Merwin RM, Sachs DH, Asofsky R (1979) Establisment and characterization of BALB/c lymphoma lines with B cell properties. J Immunol 122:549-554
41. Johnson NA, Slack GW, Savage KJ et al (2012) Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30:3452-3459
42. Kadoch C, Dinca EB, Voicu R et al (2009) Pathologic correlates of primary central nervous system lymphoma defined in an orthotopic xenograft model. Clin Cancer Res 15:1989-1997
43. Kim N, Martin TE, Simon MC, Storb U (2003) The transcription factor Spi-B is not required for somatic hypermutation. Mol Immunol 39:577-583
44. Klein U, Casola S, Cattoretti G et al (2006) Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nat Immunol 7:773-782
45. Kluin P, Deckert M, Ferry JA (2008) Primary diffuse large B-cell lymphoma of the CNS. In: Swerdlow SH, Campo E, Harris NL et al (eds) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon, pp 240-241
46. Kornelisse RF, Savelkoul HF, Mulder PH et al (1996) Interleukin-10 and soluble tumor necrosis factor receptors in cerebrospinal fluid of children with bacterial meningitis. J Infect Dis 173:1498-1502
47. Krueger M, Bechmann I (2010) CNS pericytes: concepts, misconceptions, and a way out. Glia 58:1-10
48. Krumbholz M, Theil D, Derfuss T et al (2005) BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 201:195-200
49. Kurzwelly D, Glas M, Roth P et al (2010) Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. J Neurooncol 97:389-392
50. Larocca LM, Capello D, Rinelli A et al (1998) The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center-related B cells. Blood 92:1011-1019
51. Lenz G, Wright G, Dave SS et al (2008) Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359:2313-2323
52. Lo Coco F, Ye BH, Lista F et al (1994) Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma. Blood 83:1757-1759
53. Mastroianni CM, Paoletti F, Lichtner M, D'Agostino C, Vullo V, Delia S (1997) Cerebrospinal fluid cytokines in patients with tuberculous meningitis. Clin Immunol Immunopathol 84:171-176
54. Mathieson BJ, Campbell PS, Potter M, Asofsky R (1978) Expression of Ly 1, Ly 2, Thy 1, and TL differentiation antigens on mouse T-cell tumors. J Exp Med 147:1267-1279
55. Matsumoto T, Imagama S, Hirano K et al (2012) CD44 expression in astrocytes and microglia is associated with ALS progression in a mouse model. Neurosci Lett 520:115-120
56. McHeyzer-Williams MG, McLean MJ, Nossal GJV, Lalor PA (1992) The dynamics of T cell-dependent B cell responses in vivo. Immunol Cell Biol 70:119-127
57. Mineo JF, Scheffer A, Karkoutly C et al (2008) Using human CD20-transfected murine lymphomatous B cells to evaluate the efficacy of intravitreal and intracerebral rituximab injections in mice. Invest Ophthalmol Vis Sci 49:4738-4745
58. Montesinos-Rongen M, Akasaka T, Zühlke-Jenisch R et al (2003) Molecular characterization of BCL6 breakpoints in primary diffuse large B-cell lymphomas of the central nervous system identifies GAPD as novel translocation partner. Brain Pathol 13:534-538
59. Montesinos-Rongen M, Brunn A, Bentink S et al (2008) Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell. Leukemia 22:400-405
60. Montesinos-Rongen M, Godlewska E, Brunn A, Wiestler OD, Siebert R, Deckert M (2011) Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma. Acta Neuropathol 122:791-792
61. Montesinos-Rongen M, Hans VH, Eis-Hübinger AM et al (2001) Human herpes virus-8 is not associated with primary central nervous system lymphoma in HIV-negative patients. Acta Neuropathol 102:489-495
62. Montesinos-Rongen M, Küppers R, Schlüter D et al (1999) Primary central nervous system lymphomas are derived from germinal-center B cells and show a preferential usage of the V4-34 gene segment. Am J Pathol 155:2077-2086
63. Montesinos-Rongen M, Sanchez-Ruiz M, Brunn A et al (2013) Mechanisms of intracerebral lymphoma growth delineated in a syngeneic mouse model of central nervous system lymphoma. J Neuropathol Exp Neurol 72:325-336
64. Montesinos-Rongen M, Schäfer E, Siebert R, Deckert M (2012) Genes regulating the B cell receptor pathway are recurrently mutated in primary central nervous system lymphoma. Acta Neuropathol 124:905-906
65. Montesinos-Rongen M, Schmitz R, Brunn A et al (2010) Mutations of CARD11 but not TNFAIP3 may activate the NF-kappaB pathway in primary CNS lymphoma. Acta Neuropathol 120:529-535
66. Montesinos-Rongen M, Schmitz R, Courts C et al (2005) Absence of immunoglobulin class switch in primary lymphomas of the central nervous system. Am J Pathol 166:1773-1779
67. Montesinos-Rongen M, Siebert R, Deckert M (2009) Primary lymphoma of the central nervous system: just DLBCL or not? Blood 113:7-10
68. Montesinos-Rongen M, Van Roost D, Schaller C, Wiestler OD, Deckert M (2004) Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation. Blood 103:1869-1875
69. Montesinos-Rongen M, Zühlke-Jenisch R, Gesk S et al (2002) Interphase cytogenetic analysis of lymphoma-associated chromosomal breakpoints in primary diffuse large B-cell lymphomas of the central nervous system. J Neuropathol Exp Neurol 61:926-933
70. Morse HC 3rd, Anver MR, Fredrickson TN et al (2002) Bethesda proposals for classification of lymphoid neoplasms in mice. Blood 100:246-258
71. Muldoon LL, Lewin SJ, Dosa E et al (2011) Imaging and therapy with rituximab anti-CD20 immunotherapy in an animal model of central nervous system lymphoma. Clin Cancer Res 17:2207-2215
72. Ngo VN, Young RM, Schmitz R et al (2011) Oncogenically active MYD88 mutations in human lymphoma. Nature 470:115-119
73. O'Connor PM, Wassermann K, Sarang M, Magrath I, Bohr VA, Kohn KW (1991) Relationship between DNA cross-links, cell cycle, and apoptosis in Burkitt's lymphoma cell lines differing in sensitivity to nitrogen mustard. Cancer Res 51:6550-6557
74. Ochiai K, Maienschein-Cline M, Simonetti G et al (2013) Transcriptional regulation of germinal center B and plasma cell fates by dynamical control of IRF4. Immunity 38:918-929
75. Paulus W, Jellinger K (1993) Comparison of integrin adhesion molecules expressed by primary brain lymphomas and nodal lymphomas. Acta Neuropathol 86:360-364
76. Pels H, Montesinos-Rongen M, Schaller C et al (2005) VH gene analysis of primary CNS lymphomas. J Neurol Sci 228:143-147
77. Pesic M, Bartholomäus I, Kyratsous NI, Heissmeyer V, Wekerle H, Kawakami N (2013) 2-photon imaging of phagocyte-mediated T cell activation in the CNS. J Clin Invest 123:1192-1201
78. Ponzoni M, Berger F, Chassagne-Clement C et al (2007) Reactive perivascular T-cell infiltrate predicts survival in primary central nervous system B-cell lymphomas. Br J Haematol 138:316-323
79. Ramkumar HL, de Shen F, Tuo J et al (2012) IL-10-1082 SNP and IL-10 in primary CNS and vitreoretinal lymphomas. Graefes Arch Clin Exp Ophthalmol 250:1541-1548
80. Richter J, Ammerpohl O, Martin-Subero JI et al (2009) Array-based DNA methylation profiling of primary lymphomas of the central nervous system. BMC Cancer 9:455-462
81. Rickert CH, Dockhorn-Dworniczak B, Simon R, Paulus W (1999) Chromosomal imbalances in primary lymphomas of the central nervous system. Am J Pathol 155:1445-1451
82. Riemersma SA, Oudejans JJ, Vonk MJ et al (2005) High numbers of tumour-infiltrating activated cytotoxic T lymphocytes, and frequent loss of HLA class I and II expression, are features of aggressive B cell lymphomas of the brain and testis. J Pathol 206:328-336
83. Rimsza LM, Roberts RA, Miller TP et al (2004) Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 103:4251-4258
84. Robertus JL, Harms G, Blokzijl T et al (2009) Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma. Mod Pathol 22:547-555
85. Roers A, Siewe L, Strittmatter E et al (2004) T cell-specific inactivation of the interleukin 10 gene in mice results in enhanced T cell responses but normal innate responses to lipopolysaccharide or skin irritation. J Exp Med 200:1289-1297
86. Rössler K, Neuchrist C, Kitz K, Scheiner O, Kraft D, Lassmann H (1992) Expression of leucocyte adhesion molecules at the human blood-brain barrier (BBB). J Neurosci Res 31:365-374
87. Roychowdhury S, Peng R, Baiocchi RA et al (2003) Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma. Cancer Res 63:965-971
88. Rubenstein JL, Fridlyand J, Shen A et al (2006) Gene expression and angiotropism in primary CNS lymphoma. Blood 107:3716-3723
89. Rubenstein JL, Wong VS, Kadoch C et al (2013) CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma. Blood 121:4740-4748
90. Sagardoy A, Martinez-Ferrandis JI, Roa S et al (2013) Downregulation of FOXP1 is required during germinal center B-cell function. Blood 121:4311-4320
91. Schlüter D, Löhler J, Deckert M, Hof H, Schwendemann G (1991) Toxoplasma encephalitis of immunocompetent and nude mice: immunohistochemical characterisation of toxoplasma antigen, infiltrates and major histocompatibility complex gene products. J Neuroimmunol 31:185-198
92. Schlüter D, Oprisiu SB, Chahoud S et al (1995) Systemic immunization induces protective CD4+ and CD8+ T cell-mediated immune responses in murine Listeria monocytogenes meningoencephalitis. Eur J Immunol 25:2384-2391
93. Schwindt H, Akasaka T, Zühlke-Jenisch R et al (2006) Chromosomal translocations fusing the BCL6 gene to different partner loci are recurrent in primary central nervous system lymphoma and may be associated with aberrant somatic hypermutation or defective class switch recombination. J Neuropathol Exp Neurol 65:776-782
94. Schwindt H, Vater I, Kreuz M et al (2009) Chromosomal imbalances and partial uniparental disomies in primary central nervous system lymphoma. Leukemia 23:1875-1884
95. Shapiro-Shelef M, Lin KI, McHeyzer-Williams LJ, Liao J, McHeyzer-Williams MG, Calame K (2003) Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. Immunity 19:607-620
96. Shin T, Ahn M, Kim H et al (2005) Temporal expression of osteopontin and CD44 in rat brains with experimental cryolesions. Brain Res 1041:95-101
97. Soussain C, Muldoon LL, Varallyay C, Jahnke K, DePaula L, Neuwelt EA (2007) Characterization and magnetic resonance imaging of a rat model of human B-cell central nervous system lymphoma. Clin Cancer Res 13:2504-2511
98. Stenzel W, Dahm J, Sanchez-Ruiz M et al (2005) Regulation of the inflammatory response to Staphylococcus aureus-induced brain abscess by interleukin-10. J Neuropathol Exp Neurol 64:1046-1057
99. Thompsett AR, Ellison DW, Stevenson FK, Zhu D (1999) V(H) gene sequences from primary central nervous system lymphomas indicate derivation from highly mutated germinal center B cells with ongoing mutational activity. Blood 94:1738-1746
100. Torre D, Zeroli C, Martegani R, Speranza F (1996) Levels of interleukin-10 and tumor necrosis factor alpha in patients with bacterial meningitis. Clin Infect Dis 22:883-885
101. van Furth AM, Seijmonsbergen EM, Langermans JA, Groeneveld PH, de Bel CE, van Furth R (1995) High levels of interleukin 10 and tumor necrosis factor alpha in cerebrospinal fluid during the onset of bacterial meningitis. Clin Infect Dis 21:220-222
102. Weber T, Weber RG, Kaulich K et al (2000) Characteristic chromosomal imbalances in primary central nervous system lymphomas of the diffuse large B-cell type. Brain Pathol 10:73-84
103. Ye BH, Lista F, Lo Coco F et al (1993) Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science 262:747-750
104. Yuan J, Gu K, He J, Sharma S (2013) Preferential up-regulation of osteopontin in primary central nervous system lymphoma does not correlate with putative receptor CD44v6 or CD44H expression. Hum Pathol 44:606-611